Amicus Reports Positive Preliminary Data On Plicera For Gaucher Disease
This article was originally published in The Pink Sheet Daily
Amicus and partner Shire hope to grab a share of the $1 billion market now dominated by Genzyme’s Cerezyme.
You may also be interested in...
Migalastat probably is approvable, but the threat to Genzyme’s Fabrazyme is still nominal, analysts say.
Deal valued at up to $440 million would give the U.K. firm three pharmacological chaperone compounds that could compete with Genzyme products in Gaucher, Fabry and Pompe diseases.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.